- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04858932
Geriatric Anorexia Study (GAS)
Novel Digital Endpoints in Geriatric Anorexia
Study Overview
Status
Conditions
Detailed Description
This is a study to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults. Subjects, age 65 to 85 years will be recruited.
The proposed study will consist of an initial (in-clinic) intake visit on Day 1 where the subject will be screened and enrolled in the study after signing an informed consent document, followed by an at-home phase where the subject will wear a watch like device on one wrist. After training, the subject will return for their Day 8 in-clinic visit, where the subject will repeat some intake assessments and activities, as well as some additional standing and walking activities. The subject will then be asked to perform at-home activities and assessments with the use of a smart phone, digital food scale, smart body weight scale, and continuous glucose monitor, while continuing to wear the watch-like device and a movement measurement device around their waist (Days 8-21). A final in-clinic visit will take place on Day 21 for final assessments and device collection. A +/- 4 days will be allocated for the scheduling of all visits to accommodate subject's schedules and commitments. All in-laboratory activities will take place in the Laboratory for Human Neurobiology while in-home activities will be completed in the subject's home. The study procedures will be identical for all subjects for the three groups.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Evans Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
[separated into the three groups based on the Fried Criteria: 0, 1-2, 3 or above]
- Male or female participants aged 65 - 85 years.
- No clinically significant health problems other than well controlled chronic conditions (e.g., allergies and dermatitis)
- No recent hospitalizations/acute events in last 12 months.
- No active or recent (within 12 months) cancer diagnosis except skin cancer (limited to only non-complicated Squamous Cell Carcinoma (SCC)/Basal Cell Carcinoma (BCC)).
- Body mass index (BMI) < 30 kg/m2
- Able to understand and cooperate with study procedures and able to read, understand and provide informed consent. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study
- Participants should not have any food aversion which could influence their food selection if standardized meals are used as part of the protocol.
- Native English speakers or demonstrated fluency in English as determined by the Investigator.
- Wide Range Achievement Test (WRAT-4) Word Reading Subtest equivalent to 8th grade reading level or greater.
- Normal or corrected-to-normal vision
Exclusion Criteria:
- Treatment with an investigational drug within 30 days of enrollment
- A moderate to severe alcohol use disorder diagnosis within 6 months of the screening as disclosed by the subject
- Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Boston University/Boston Medical Center directly involved in the conduct of the study
- Inability to comply with study requirements.
- Has any clinically significant medical disorder, condition, disease or clinically significant finding at screening that precludes subject's participation in study activities including any self-reported diagnosis of eating disorders.
- Participants with electronic implant devices, such as pacemaker.
- Non-English Reader as measured by the WRAT-4.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fried Frailty Phenotype 0
Those who are considered Robust under the Fried Frailty Criteria.
Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
|
a watch like wearable sensor
Other Names:
a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
Other Names:
a scale to measure food weight
Other Names:
a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
Other Names:
|
Fried Frailty Phenotype 1-2
Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria.
Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
|
a watch like wearable sensor
Other Names:
a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
Other Names:
a scale to measure food weight
Other Names:
a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
Other Names:
|
Fried Frailty Phenotype 3+
Those who are considered Frail under the Fried Frailty Criteria.
Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
|
a watch like wearable sensor
Other Names:
a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
Other Names:
a scale to measure food weight
Other Names:
a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the feasibility, usability, and compliance of wearing a GENEActiv watch in a geriatric population both in-clinic and remotely at-home.
Time Frame: 21 days +/- 4 days
|
One GENEActiv watch will be used on one wrist and one around the waist at a sampling rate of 50 Hz to measure movement in the x, y, and z direction across the study period.
|
21 days +/- 4 days
|
Assess the feasibility, usability, and compliance of food consumption tracking in a geriatric population both in-clinic and remotely at-home.
Time Frame: 21 days +/- 4 days
|
A food scale will be used to track food consumed in grams (g) throughout the study.
The total number of meals consumed per day and across study period.
|
21 days +/- 4 days
|
Assess the feasibility, usability, and compliance of body weight composition measurements in a geriatric population both in-clinic and remotely at-home.
Time Frame: 21 days +/- 4 days
|
A body weight composition scale will be used to completion of daily weight measurement and track body weight in kilograms (kg) throughout the study.
|
21 days +/- 4 days
|
Assess the correlation of a GENEActiv watch with frailty phenotype in elderly participants.
Time Frame: 21 days +/- 4 days
|
One GENEActiv watch will be used on one wrist and one around the waist at a sampling rate of 50 Hz to measure movement in the x, y, and z direction.
This data will be compared to frailty phenotype per the Fried Frailty Scale and continuous glucose measurements.
|
21 days +/- 4 days
|
Assess the correlation of food consumption with frailty phenotype in elderly participants.
Time Frame: 21 days +/-4 days
|
A food scale will be used to track food consumed in grams (g) throughout the study.
This data will be compared to frailty phenotype per the Fried Frailty Scale.
|
21 days +/-4 days
|
Assess the correlation of the body weight composition scale with frailty phenotype in elderly participants.
Time Frame: 21 days +/-4 days
|
A body weight composition scale will be used to track body weight in kilograms (kg) throughout the study.
This data will be compared to frailty phenotype per the Fried Frailty Scale.
|
21 days +/-4 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin C Thomas, PhD, MBA, Principal Investigator, Boston University, Department of Anatomy & Neurobiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-40837
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Wrist Actigraphy Device
-
AbbVieTerminated
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedHIV Infections | SleepUnited States
-
Boston UniversityCompleted
-
Boston UniversityCompleted
-
Philips Clinical & Medical Affairs GlobalCompleted
-
Taipei Medical UniversityTaipei Medical University Hospital; Taipei Medical University WanFang Hospital and other collaboratorsCompletedNeoplasm of Breast (Disorder) | Carcinoma of Prostate (Disorder)Taiwan
-
Shanghai Jiao Tong University School of MedicineRuijin HospitalCompletedSleep DisordersChina
-
Cala Health, Inc.Not yet recruiting
-
Hoffmann-La RocheCompletedNon-Small Cell Lung Cancer (NSCLC)Spain